Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISAPS: rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome
ISRCTN10280992Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in antiphospholipid syndrome (APS) comparing Rivaroxaban with Warfarin (2 arms). Primary endpoint: Rate of change in brain white matter hyperintensity volume. Started Jul 2021; status: completed.
02
Drugs
rivaroxabanwarfarin
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on ISRCTN10280992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10280992.